Transactivation of ERBB family of receptor tyrosine kinases is inhibited by angiotensin-(1-7) via its mas receptor

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Akhtar, Saghir ^a   Chandrasekhar, Bindu ^a   Attur, Sreeja ^a   Dhaunsi, Gursev S ^a   Yousif, Mariam H M ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUCOSE; I KAPPA B ALPHA; MAS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NORADRENALIN; PROTEIN TYROSINE KINASE; RECEPTOR; RHO KINASE; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; VASODILATOR AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; HYPERGLYCEMIA; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WISTAR RAT;

ANGIOTENSIN I; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ERBB RECEPTORS; GENE EXPRESSION REGULATION; GLUCOSE; MALE; MUSCLE, SMOOTH, VASCULAR; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; VASODILATOR AGENTS;

EID: 84951025543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141657     Document Type: Article

References (48)

1. Gray SP, Jandeleit-Dahm K. The pathobiology of diabetic vascular complications-cardiovascular and kidney disease. J Mol Med (Berl). 2014; 92: 441-452.
2. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93: 137-88. doi: 10.1152/physrev.00045.2011 PMID: 23303908
3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058-1070. doi: 10.1161/CIRCRESAHA.110.223545 PMID: 21030723
4. Akhtar S, Yousif MH, Dhaunsi GS, Sarkhouh F, Chandrasekhar B, Attur S et al., (2013). Activation of ErbB2 and Downstream Signaling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. PLoS One 8: e67813. PMID: 23826343
5. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol. 2012a; 165: 1390-1400.
6. Akhtar S, Benter IF. The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. BioImpacts. 2013; 3: 5-9. doi: 10.5681/bi.2013.008 PMID: 23678464
7. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S (2005a). Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 145: 829-836.
8. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S (2005b). Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 42: 284-291.
9. Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S (2009). Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul Pharmacol 51: 236-245. doi: 10.1016/j.vph.2009.06.008 PMID: 19577003
10. Galán M, Kassan M, Choi SK, Partyka M, Trebak M, Henrion D et al. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension. 2012; 60: 71-80. doi: 10. 1161/HYPERTENSIONAHA.112.192500 PMID: 22665120
11. Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev. 2010; 26: 13-16. doi: 10.1002/dmrr.1050 PMID: 19943320
12. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79: 34-74. doi: 10.1016/j.phrs.2013.11.002 PMID: 24269963
13. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160-74. Erratum in: N Engl J Med. 2009; 360: 1579. doi: 10.1056/NEJMra0707704 PMID: 18337605
14. Bełtowski J, Jazmroz-Wis̈niewska A (2014). Transactivation of ErbB receptors by leptin in the cardiovascular system: mechanisms, consequences and target for therapy. Curr Pharm Des 20: 616-24. PMID: 23688012
15. Sur S, Agrawal DK. Transactivation of EGFR by G protein-coupled receptor in the pathophysiology of intimal hyperplasia. Curr Vasc Pharmacol. 2014; 12(2): 190-201. PMID: 24568153
16. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by Gprotein-coupled receptors. Nature. 1996; 379(6565): 557-60. PMID: 8596637
17. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 2007; 112: 417-28.
18. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol. 2011; 331(2): 222-31 doi: 10.1016/j.mce.2010.04.008 PMID: 20398727
19. Ulu N, Gurdal H, Landheer SW, Duin M, Guc MO, Buikema H, et al. α1-Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. Br J Pharmacol. 2010; 161(6): 1301-10. doi: 10.1111/j.1476-5381.2010.00829.x PMID: 20977469
20. Yousif MH, Benter IF, Akhtar S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol. 2005; 25: 69-78. PMID: 15757506
21. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: Renin-Angiotensin-aldosterone system alterations. Circ Res. 2015; 116: 960-75. doi: 10.1161/CIRCRESAHA.116. 303587 PMID: 25767283
22. Pernomian L, Pernomian L, Baraldi Araújo Restini C. Counter-regulatory effects played by the ACE-Ang II-AT1 and ACE2-Ang-(1-7)-Mas axes on the reactive oxygen species-mediated control of vascular function: perspectives to pharmacological approaches in controlling vascular complications. Vasa. 2014; 43(6): 404-14. doi: 10.1024/0301-1526/a000387 PMID: 25339158
23. Patel VB, Parajuli N, Oudit GY. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond). 2014; 126: 471-82.
24. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014; 4: 201.
25. McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA. Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci (Lond). 2014; 126: 815-27.
26. Benter IF, Diz DI, Ferrario CM (1993). Cardiovascular actions of angiotensin(1-7). Peptides 14: 679-84. PMID: 8234010
27. Benter IF, Ferrario CM, Morris M, Diz DI (1995). Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol. 269(1 Pt 2):H313-9. PMID: 7631863
28. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI (2007). Angiotensin-(1-7) prevents diabetesinduced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666-72. PMID: 17213482
29. Yousif MH, Makki B, El-Hashim AZ, Akhtar S, Benter IF. Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes. J Diabetes Res. 2014; 2014: 142154. doi: 10.1155/2014/142154 PMID: 25309930
30. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC, Diz DI (2011). Angiotensin-(1-7) blockade attenuates captopril-or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester. J Cardiovasc Pharmacol 57: 559-67. doi: 10.1097/FJC.0b013e31821324b6 PMID: 21326110
31. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One. 2012b; 7: e39066.
32. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K (2008). Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 1629-1637. doi: 10.2337/db07-0739 PMID: 18319304
33. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/ Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015; 5: 8209. doi: 10.1038/srep08209 PMID: 25644821
34. Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L et al. Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br J Pharmacol. 2014; 171: 4222-32. doi: 10.1111/bph.12770 PMID: 24824997
35. Costa A, Galdino G, Romero T, Silva G, Cortes S, Santos R et al. Ang-(1-7) activates the NO/cGMP and ATP-sensitive K+ channels pathway to induce peripheral antinociception in rats. Nitric Oxide. 2014; 37: 11-6. doi: 10.1016/j.niox.2013.12.007 PMID: 24361899
36. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-κB-dependent pathways. Br J Pharmacol. 2012; 166: 1964-1976. doi: 10.1111/j.1476-5381.2012.01905.x PMID: 22339213
37. Al-Maghrebi M, Benter IF, Diz DI (2009). Endogenous angiotensin-(1-7) reduces cardiac ischemiainduced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-8. doi: 10.1016/j.phrs.2008. 12.008 PMID: 19166939
38. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Aktdependent pathways. Hypertension. 2007; 49: 185-92. PMID: 17116756
39. Tao X, Fan J, Kao G, Zhang X, Su L, Yin Y et al. Angiotensin-(1-7) attenuates angiotensin II-induced signalling associated with activation of a tyrosine phosphatase in Sprague-Dawley rats cardiac fibroblasts. Biol Cell. 2014; 106: 182-92. doi: 10.1111/boc.201400015 PMID: 24641355
40. Souza LL, Costa-Neto CM. Angiotensin-(1-7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol. 2012; 227: 2117-22. doi: 10.1002/jcp.22940 PMID: 21769868
41. Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F (2015). Renin-Angiotensin System: An Old Player with Novel Functions in Skeletal Muscle. Med Res Rev. doi: 10.1002/med.21343
42. Cao X, Yang FY, Xin Z, Xie RR, Yang JK. The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance. Mol Cell Endocrinol. 2014; 393: 30-8. doi: 10.1016/j.mce.2014.05.024 PMID: 24911884
43. Fu Z, Zhao L, Aylor KW, Carey RM, Barrett EJ, Liu Z. Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor. Hypertension. 2014; 63: 1219-27. doi: 10.1161/HYPERTENSIONAHA.113.03025 PMID: 24711523
44. Martinez-Useros J, Garcia-Foncillas J. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncol. 2015. doi: 10.1016/j.oraloncology. 2015.02.092
45. Price KA, Cohen EE. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015. doi: 10.1016/j.oraloncology.2015.01.018
46. Wang X, Batty KM, Crowe PJ, Goldstein D, Yang JL. The Potential of panHER Inhibition in Cancer. Front Oncol. 2015; 5: 2. doi: 10.3389/fonc.2015.00002 PMID: 25674538
47. Gallagher PE, Arter AL, Deng G, Tallant EA. Angiotensin-(1-7): a peptide hormone with anti-cancer activity. Curr Med Chem. 2014; 21: 2417-23. PMID: 24524765
48. Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, et al. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. J Drug Target. 2015; 23: 506-18. doi: 10.3109/1061186X.2015.1057150 PMID: 26114862